| | Subsequent invasive breast cancera | Ipsilateral invasive breast cancerb | Contralateral invasive breast cancerc |
|---|
Person-years | Cases | HRd (95% CI) | Person-years | Cases | HRe (95% CI) | Person-years | Cases | HRf (95% CI) |
|---|
White | 130,213 | 1264 | 1.00 | 120,334 | 722 | 1.00 | 128,949 | 521 | 1.00 |
Black | 11,935 | 142 | 1.33 (1.11, 1.59) | 11,283 | 85 | 1.37 (1.08, 1.72) | 11,818 | 57 | 1.33 (1.00, 1.76) |
Asian | 6434 | 55 | 0.83 (0.62, 1.10) | 6137 | 33 | 0.87 (0.61, 1.25) | 6406 | 22 | 0.78 (0.49, 1.24) |
Hispanic | 12,229 | 106 | 0.89 (0.72, 1.09) | 11,564 | 70 | 0.99 (0.77, 1.27) | 12,142 | 36 | 0.76 (0.54, 1.08) |
- Abbreviations: HR hazard ratio, 95% CI 95% confidence interval
- aSubsequent invasive breast cancer included invasive breast cancer in either breast and metastatic breast cancer. The analysis included 19,545 women with LCIS
- bThe analysis was restricted to 17,843 women who did not have surgical treatment or received breast-conserving surgery for primary LCIS
- cThe analysis was restricted to 18,642 women who did not have surgical treatment or received breast-conserving surgery or unilateral mastectomy for primary LCIS
- dHRs were adjusted for age (20–39, 40–49, 50–59, 60–69, or ≥ 70 years) and year of the initial LCIS diagnosis (1990–1999, 2000–2009, or 2010–2015), registry, and treatment for primary LCIS (no surgical treatment, breast-conserving surgery alone, breast-conserving surgery followed by radiation therapy, mastectomy, or unknown)
- eThe covariates were the same as the above. Treatment was categorized as no surgical treatment, breast-conserving surgery alone, or breast-conserving surgery followed by radiation therapy
- fThe covariates were the same as the above. Treatment was categorized as no surgical treatment, breast-conserving surgery alone, breast-conserving surgery followed by radiation therapy, or mastectomy
